Chloroquine-resistant Plasmodium vivax malaria in Debre Zeit, Ethiopia

BACKGROUND: Plasmodium vivax accounts for about 40% of all malaria infection in Ethiopia. Chloroquine (CQ) is the first line treatment for confirmed P. vivax malaria in the country. The first report of CQ treatment failure in P. vivax was from Debre Zeit, which suggested the presence of chloroquine...

Descripción completa

Detalles Bibliográficos
Autores principales: Teka, Hiwot, Petros, Beyene, Yamuah, Lawrence, Tesfaye, Gezahegn, Elhassan, Ibrahim, Muchohi, Simon, Kokwaro, Gilbert, Aseffa, Abraham, Engers, Howard
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2584068/
https://www.ncbi.nlm.nih.gov/pubmed/18959774
http://dx.doi.org/10.1186/1475-2875-7-220

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2584068/
https://www.ncbi.nlm.nih.gov/pubmed/18959774
http://dx.doi.org/10.1186/1475-2875-7-220

Ejemplares similares